| __timestamp | Bristol-Myers Squibb Company | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 1802274 |
| Thursday, January 1, 2015 | 5001000000 | 2512761 |
| Friday, January 1, 2016 | 5002000000 | 2894488 |
| Sunday, January 1, 2017 | 4849000000 | 8096274 |
| Monday, January 1, 2018 | 4551000000 | 7985229 |
| Tuesday, January 1, 2019 | 4871000000 | 8994597 |
| Wednesday, January 1, 2020 | 7661000000 | 29772000 |
| Friday, January 1, 2021 | 7690000000 | 33907000 |
| Saturday, January 1, 2022 | 7814000000 | 26579000 |
| Sunday, January 1, 2023 | 7772000000 | 49868547 |
| Monday, January 1, 2024 | 8414000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Bristol-Myers Squibb Company (BMY) and Verona Pharma plc (VRNA) have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Bristol-Myers Squibb, a titan in the industry, consistently allocated substantial resources, with SG&A expenses peaking at approximately $7.8 billion in 2022, reflecting a 37% increase from 2014. In contrast, Verona Pharma, a smaller player, demonstrated a more conservative approach, with expenses growing from $1.8 million in 2014 to nearly $50 million in 2023, marking a staggering 2,670% rise. This divergence highlights the scale and strategic priorities of each company, offering insights into their operational frameworks. As the pharmaceutical sector continues to innovate, understanding these financial dynamics is crucial for stakeholders and investors alike.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Who Optimizes SG&A Costs Better? Verona Pharma plc or MorphoSys AG
Who Optimizes SG&A Costs Better? Verona Pharma plc or Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights